Rates of mastectomy for breast cancer treatment and immediate reconstruction continue to rise. With increasing scrutiny on outcomes and patient satisfaction, there is an impetus for providers to be more deliberate in deciding appropriate patient selection for breast reconstruction. The Breast Reconstruction Risk Assessment (BRA) Score was developed for prediction of complications after primary prosthetic breast reconstruction, focusing on calculating risk estimations for a variety of complications based on individual patient demographics and perioperative characteristics. In this study, we evaluate mastectomy skin flap necrosis (MSFN) as a function of patient characteristics to further validate the BRA Score.
We examined our prospective intra-institutional database of prosthetic breast reconstructions from 2004- 2015. Outcomes of interest were 1-year occurrence of MSFN following stage I tissue expander placement.
903 patients were included; 50% underwent bilateral reconstruction. Median follow-up was 23 months. Average 1-year complication rates were: MSFN (12.4%), seroma (3.0%), infection (6.9%), dehiscence/exposure (7.1%), and explantation (13.2%). Statistically significant higher rates of MSFN were found in older patients, smokers, patients with postoperative infections, hypertension and the use of aspirin. Neoadjuvant or adjuvant chemotherapy and radiation, diabetes and seroma formation did not have a statistically significant impact on necrosis rates.
The BRA Score was expanded to estimate complication risk following tissue expander placement up to one year postoperatively. The risk of MSFN as calculated by the BRA Score XL is consistent with published studies demonstrating increased risk with specific comorbidities and further validates the expansion of the BRA Score risk calculator.